Grossi E A, Galloway A C, Zakow P K, Miller J S, Buttenheim P M, Baumann F G, Culliford A T, Spencer F C, Colvin S B
Department of Surgery, New York University Medical Center, NY 10016, USA.
Circulation. 1998 Nov 10;98(19 Suppl):II116-9.
In younger patients requiring mitral valve replacement (MVR), mechanical prostheses (MPs) have been reported to give better freedom from all valve-related complications (VRCs) because of the high incidence of late valve degeneration (VD) associated with bioprostheses (BPs). In older patients, however, the risk of VD may be reduced because of the large competing risk of noncardiac death (NCD). Previous studies on VD in the elderly have used actuarial analysis, which overestimates the risk of VD in this population because it assumes that dead patients are still at risk. In contrast, cumulative incidence (actual) analysis acknowledges that patients who die have no risk of VD. This study compares the results of both "actual" and "actuarial" analyses of the freedom from VD in elderly patients undergoing MVR.
From June 1976 through January 1996, 504 patients > or = 70 years of age underwent MVR at our institution. Isolated mitral operations were performed in 159 patients, and 169 had concomitant CABG. Hospital mortality was 59 of 374 (15.9%) for tissue prosthesis versus 24 of 130 (18.5%) for mechanical prosthesis (P = NS). For tissue versus mechanical prosthesis, 10-year freedom from noncardiac death was 75.0% versus 67.6% (P = NS); 10-year actuarial freedom from valve degeneration was 79.8% versus 93.4% (P = NS); 10-year actual freedom from valve degeneration was 92.6% versus 95.4% (P = NS); and 10-year actual freedom from all VRCs was 84.4% versus 92.3% (P = NS).
In elderly patients undergoing MVR, actuarial analysis overestimates the 10-year risk of VD compared with actual analysis (20.2% versus 7.4% for BP, 6.6% versus 4.6% for MP). In these patients, the actual freedoms from VD and all VRCs do not differ significantly between BP and MP. Thus, in this age group, the necessity for anticoagulation or its avoidance may be the predominant factor in choosing a replacement mitral valve.
在需要进行二尖瓣置换术(MVR)的年轻患者中,由于生物瓣膜(BP)相关的晚期瓣膜退变(VD)发生率较高,据报道机械瓣膜(MP)在避免所有瓣膜相关并发症(VRC)方面表现更佳。然而,在老年患者中,由于非心脏死亡(NCD)这一较大的竞争风险,VD的风险可能会降低。以往关于老年人VD的研究采用精算分析,该方法高估了这一人群中VD的风险,因为它假定死亡患者仍处于VD风险中。相比之下,累积发病率(实际)分析承认死亡患者没有VD风险。本研究比较了接受MVR的老年患者中VD-free的“实际”和“精算”分析结果。
从1976年6月至1996年1月,504例年龄≥70岁的患者在我们机构接受了MVR。159例患者进行了单纯二尖瓣手术,169例患者同时进行了冠状动脉旁路移植术(CABG)。组织瓣膜组374例中有59例(15.9%)发生医院死亡,机械瓣膜组130例中有24例(18.5%)发生医院死亡(P = 无显著性差异)。对于组织瓣膜与机械瓣膜,10年非心脏死亡-free率分别为75.0%和67.6%(P = 无显著性差异);10年精算VD-free率分别为79.8%和93.4%(P = 无显著性差异);10年实际VD-free率分别为92.6%和95.4%(P = 无显著性差异);10年实际所有VRC-free率分别为84.4%和92.3%(P = 无显著性差异)。
在接受MVR的老年患者中,与实际分析相比,精算分析高估了10年VD风险(BP分别为20.2%和7.4%,MP分别为6.6%和4.6%)。在这些患者中,BP和MP之间VD-free及所有VRC-free的实际情况无显著差异。因此,在这个年龄组中,抗凝的必要性或避免抗凝可能是选择二尖瓣置换瓣膜的主要因素。